CABA - Cabaletta gets FDA orphan drug status for systemic sclerosis drug
2024-03-20 11:54:00 ET
More on Cabaletta Bio
- Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
- Cabaletta Bio gains on FDA fast-track tags for lead asset
- Seeking Alpha’s Quant Rating on Cabaletta Bio
- Historical earnings data for Cabaletta Bio
- Financial information for Cabaletta Bio